原发性轻链型淀粉样变性治疗中出现急性肝衰竭1例报告

徐锡晶; 王尧; 孙颖; 温晓玉; 靳凤艳; 金清龙

doi:10.3969/j.issn.1001-5256.2017.12.030

原发性轻链型淀粉样变性治疗中出现急性肝衰竭1例报告

DOI: 10.3969/j.issn.1001-5256.2017.12.030

1. 吉林大学第一医院肝胆胰内科
2. 吉林大学第一医院血液肿瘤科

详细信息

中图分类号: R575.3;R597.2
计量
- 文章访问数: 1349
- HTML全文浏览量: 13
- PDF下载量: 390
- 被引次数: 0
出版历程
- 出版日期: 2017-12-20

Acute liver failure during therapy for primary light-chain amyloidosis:a case report

Department of Hepatology, The First Hospital of Jilin University

摘要

摘要: <正>淀粉样变性常可累及肾脏、心脏、皮肤、消化系统和骨髓[1],分为原发性淀粉样变性、继发性淀粉样变性、透析相关性淀粉样变性及遗传性淀粉样变性。淀粉样变性的整体发病率低,其中原发性淀粉样变性发病率约为0.051‰~0.128‰[2]。该病的诊断主要依赖于病理学检查,早期临床症状隐匿,患者常因多脏器受损后就诊,临床上易误诊、漏诊。淀粉样变性累及肝脏时黄疸发生率较低(<5%),且多为轻度黄
- 淀粉样变性 /
- 肝功能衰竭,急性 /
- 病例报告
- amyloidosis /
- acute liver failure /
- case reports

HTML全文

参考文献(15)

[1]IKEDA S.Diagnosis and treatment in systemic amyloidosis[J].Rinsho Byori, 2008, 56 (2) :121-129.

[2]COHEN AD, COMENZO RL.Systemic lingt-chain amyloidosis:advances in diagnosis, program, and therapy[J].Hematology AMSoc Hematol Educ Program, 2010, 2010 (6) :287-294.

[3]LIU CJ, CHIEN RN, HUANG SF, et al.Severe intrahepatic cholestasis in an elderly patient with primary amyloidosis and colon adenocarcinoma[J].Chang Gung Med J, 2004, 27 (1) :74-79.

[5]PARK MA, MUELLER PS, KYLE RA, et al.Primary (AL) hepatic amyloidosis:clinical features and natural history in 98 patients[J].Medicine (Baltimore) , 2003, 82 (5) :291-298.

[6]HUANG FX, LUO KQ.A clinical analysis of 39 cases of amyloidosis[J].Guangdong Med J, 2001, 22 (10) :925-926.黄锋先, 罗克勤.淀粉样变性病39例临床分析[J].广东医学, 2001, 22 (10) :925-926.

[7]YAN WJ, LUO XY, YANG YS, et al.Clinical analysis of 7 patients with hepatic amyloidosis[J].Chin J Gastroenterol Hepatoll, 2013, 21 (4) :339-341. (in Chinese) 闫文姬, 罗小洋, 杨云生, 等.7例肝淀粉样变性的临床分析[J].胃肠病学和肝病学杂志, 2013, 21 (4) :339-341.

[8] LU J, WANG H, HUANG XJ.Curative effect observation of patients with primary systemic amyloidosis treated by the combination of bortezomib with dexmethasone and cyclophosphamide[J].Chin JHematol, 2013, 34 (4) :345-348. (in Chinese) 路瑾, 王辉, 黄晓军.硼替佐米联合地塞米松、环磷酰胺治疗原发性系统性淀粉样变性疗效观察[J].中华血液学杂志, 2013, 34 (4) :345-348.

[9]DISPENZIERI A, KYLE RA, LACY MQ, et al.Superi or survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation:a case control study[J].Blood, 2004, 103 (10) :3960-3963.

[10]GERTZ MA, KYLE RA.Hepatic amyloidosis:clinical appraisal in77patients[J].Hepatology, 1997, 25 (1) :118-121.

[11]CULAFIC D, PERISIC M, BORICIC I, et al.Primary amyloidisis presenting with cholestasis and hyperkinetic portal hypertension[J].JGastrointestin Liver Dis, 2007, 16 (2) :201-204.

[12]FERREIRA S, BALDAIAL C, FATELA N, et al.Severe intrahepatic cholestasis, erythrocytosis and hypoglycemia:Unusual presenting features of systemic AL amyloidosis[J].Scand J Gastroenterol, 2008, 43 (3) :375-379.

[13]PARK WJ, KIM SY, KIM YR, et al.Bortezomib alleviates druginduced liver injury by regulating CYP2E1 gene transcription[J].Int J Mol Med, 2016, 37 (3) :613-622.

[14]GERMOUSH MO.Diosmin protects against cyclophosphamide-induced liver injury through attenuation of oxidative stress, inflammation and apoptosis[J].Int J Pharmacol, 2016, 12 (6) :644-654.

[15]BAO XL, TIAN Z, CHEN QF, et al.One case of primary hepatic amyloidosis characterized by jaundic[J].J Clin Hepatol, 2013, 29 (12) :943-944. (in Chinese) 鲍旭丽, 田洲, 陈庆峰, 等.以黄疸为特征的原发性肝淀粉样变性1例报告[J].临床肝胆病杂志, 2013, 29 (12) :943-944.

施引文献

资源附件(0)

访问统计